Condition
Gastric or Esophagogastric Junction Adenocarcinoma clinical trials and research
As of November 12, 2026, Find a Trial lists 2 Gastric or Esophagogastric Junction Adenocarcinoma clinical trials that are recruiting, in China. By phase: Phase 2 (2). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 2Clinical trials
- 1Country
All recruiting trials (2)
-
Neoadjuvant Tislelizumab with LM-302 plus S-1 or with SOX for CLDN18.2-positive gastric and gastroesophageal junction adenocarcinoma.
This trial tests whether giving Tislelizumab together with a CLDN18.2-targeting agent (LM-302) plus S-1 or giving Tislelizumab with oxaliplatin and S-1 before surgery helps people with CLDN18.2-positive, locally advanced gastric or GEJ adenocarcinoma.
-
LM-302 plus oral S-1 and intraperitoneal paclitaxel, with or without cadonilimab, for Claudin 18.2–positive advanced stomach or GEJ cancer with peritoneal spread
This trial tests whether adding cadonilimab to LM-302, oral S-1, and intraperitoneal paclitaxel helps people with Claudin 18.2–positive gastric or gastroesophageal junction cancer that has spread to the peritoneum.
Related topics
Quick answers
How many Gastric or Esophagogastric Junction Adenocarcinoma clinical trials are recruiting right now?
2, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
All of them have sites in China. Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 2: 2. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.